Switzerland has solidified its position as the global anchor of the Antibody-Drug Conjugate (ADC) industry, uniquely combining massive pharmaceutical headquarters with the world's most advanced manufacturing infrastructure.

Often referred to as the "Alpine ADC Hub," the Swiss ecosystem is defined by its two-pronged dominance: commercial-scale bioconjugation and non-oncology innovation. Switzerland is home to Lonza, the world’s leading ADC manufacturer, which produces nearly 20% of global commercial supply. Beyond production, Swiss biotechs are pioneering the expansion of ADC technology into "new frontiers," such as organ fibrosis (Alentis Therapeutics) and neurology (Mabylon), making it the primary destination for the most complex "next-gen" targeted therapies. Homegrown Swiss ADC Biopharma & Research Institutes Switzerland's native ecosystem is a global leader in both clinical-stage pipelines and specialised conjugation platforms.